(c) Dr. Yossi (Joseph) Tam

Created by Yitzchak Yadegari

Publications //

2020

  • Permyakova A, Gammal A, Hinden L, Weitman M, Weinstock M, Tam J (2020) A Novel Indoline Derivative Ameliorates Diabesity-Induced Chronic Kidney Disease by Reducing Metabolic Abnormalities. Frontiers in Endocrinology doi: 10.3389/fendo.2020.00091

  • Udi S, Hinden L, Ahmad M, Drori A, Iyer MR, Cinar R, Herman-Edelstein M, Tam J (2020) Dual Inhibition of Cannabinoid-1 Receptor and iNOS Attenuates Obesity-induced Chronic Kidney Disease. Br J Pharmacol, 177(1):110-127.

2019

  • Eger M, Bader M, Bree D, Hadar R, Nemerovski A, Tam J, Levy D, Pick C, Gabet Y (2019) Bone Anabolic Response in the Calvaria Following Mild Traumatic Brain Injury Is Mediated by the Cannabinoid-1 Receptor. Sci Rep, 9:16196.

  • Baraghithy S, Smoum R, Attar-Namdar M, Mechoulam R, Bab I, Tam J (2019) HU-671, a Novel Oleoyl Serine Derivative, Exhibits Enhanced Efficacy in Reversing Ovariectomy-Induced Osteoporosis and Bone Marrow Adiposity. Molecules 24(20), 3719.

  • El-Atawneh S, Hirsch S, Hadar R, Tam J, Goldblum A (2019) Prediction and Experimental Confirmation of Novel Peripheral Cannabinoid1 Receptor Antagonists. J Chem Inf Model, 59(9):3996-4006.

  • Braxton TM, Sarpong DE, Dovey JL, Guillou AT, Evans BT, Castellano JM, Keenan BE, Baraghithy S, Evans SL, Tena-Sempere M, Mollard P, Tam J, Wells T (2019) Thermoneutrality improves skeletal impairment in adult Prader-Willi syndrome mice. J Endocrinol, 243:175–186. 

  • Hirsch S, Tam J (2019) Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome. Toxins, 11(5): 275.

  • Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, Tam J, Aqeilan R (2019) WWOX somatic ablation in skeletal muscles alters glucose metabolism. Mol. Metab., 22:132-140.

  • Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, Schnapp A, Cassuto H, Wattad N, Tam J (2019) Lower Circulating Endocannabinoid Levels in Children with Autism Spectrum Disorder. Mol Autism, 10:2.

  • Hinden L, Tam J (2019) Do Endocannabinoids Regulate Glucose Reabsorption in the Kidney? Nephron,11:1-4.

  • Baraghithy S, Smoum R, Drori A, Hadar R, Gammal A, Hirsch S, Attar-Namdar M, Nemirovski A, Gabet Y, Langer Y, Pollak Y, Schaaf CP, Rech ME, Gross-Tsur V, Bab I, Mechoulam R, Tam J (2019) Magel2 Modulates Bone Remodeling and Mass in Prader Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. J Bone Miner Res. 34:93-105.

  • Azar S, Sherf-Dagan S, Nemirovski A, Webb M, Raziel A, Keidar A, Goitein D, Sakran N, Shibolet O, Tam J, Zelber-Sagi S (2019) Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans. Obes Surg29:268-276.

  • Drori A, Permyakova A, Hadar R, Udi S, Nemirovski A, Tam J (2019) Cannabinoid-1 Receptor Regulates Mitochondrial Dynamics and Function in Renal Proximal Tubular Cells. Diabetes Obes Metab. 21:146-159.

2018

  • Zachut M, Kra G, Moallem U, Livshitz L, Levin Y, Udi S, Nemirovski A, Tam J (2018) Characterization of the Endocannabinoid System in Subcutaneous Adipose Tissue in Periparturient Dairy Cows and its Association to Metabolic Profiles. PLoS One., 13:e0205996.

​​

  • Ganot N, Braitbard O, Gammal A, Tam J, Hochman J, Tshuva EY (2018) In Vivo Anticancer Activity of a Non‐Toxic Inert Phenolato Ti Complex: High Efficacy on Solid Tumors Alone and Combined with Pt Drugs. Chem Med Chem. 13:2290-2296.

  • Tam J, Hinden L, Drori A, Udi S, Azar S, Baraghithy S (2018) The Therapeutic Potential of Targeting the Peripheral Endocannabinoid/CB1 Receptor System. Eur J Intern Med, 49:23-29. 

  • Deis S, Srivastava RK, de Azua IR, Bindila L, Baraghithy S, Lutz B, Bab I, Tam J (2018) Age-related regulation of bone formation by the sympathetic cannabinoid CB1 receptor. Bone 108:34-42.

  • Hinden L, Udi S, Drori A, Gammal A, Nemirovski A, Hadar R, Baraghithy S, Permyakova A, Geron M, Cohen M, Tsytkin-Kirschenzweig S, Riahi Y, Leibowitz G, Nahmias Y, Priel A, Tam J (2018) Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy. J Am Soc Nephrol, 29:434-448.

2017

  • Drori A, Rotnemer-Golinkin D, Avni S, Drori A, Danay O, Levanon D, Tam J, Zolotarev L, Ilan Y (2017) Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift. BMC Gastroenterol, 17:130.

  • Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J​ (2017) Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-induced Chronic Kidney Disease. J Am Soc Nephrol  28:3518-3532.

  • Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R, Shpitzen S, Udi S, Tam J, Heeren J, Worthmann A, Schramm C, Kluwe J, Ravid R, Hornstein E, Giladi H, Galun E (2017) Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues. Gastroenterology 153:1404-1415.

  • Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G (2017) Peripheral Cannabinoid-1 Receptor Blockade Restores Hypothalamic Leptin Signaling. Mol Metab. 6:1113-1125.

  • Hanin G, Yayon N, Tzur Y, Haviv R, Bennett ER, Udi S, Krishnamoorthy YR, Kotsiliti E, Zangen R, Efron B, Tam J, Pappo O, Shteyer E, Pikarsky E, Heikenwalder M, Greenberg DS, Soreq H (2017) miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 67:1124-1134.

  • Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, Tam J (2017) Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity. 25:94-101.

2016

  • Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, Cinar C, Hirsch HJ, Pollak Y, Gross I, Eldar-Geva T, Reyes-Capo DP, Han JC, Haqq AM, Gross-Tsur V, Wevrick R, Tam J. (2016) Targeting the Endocannabinoid/CB1 Receptor System for Treating Obesity in Prader-Willi Syndrome. Mol Metab, 5:1187-1199.​

  • Tam J (2016) The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. J Basic Clin Physiol Pharmacol. 27:267-76.

2015

  • Tam J. (2015) Role of the Endocannabinoid System in Hepatic Lipogenesis, Hepatic De novo Lipogenesis and Regulation of Metabolism, James M Ntambi, Editor, Springer.

 

  • Godlewski G, Jourdan T, Szanda G, Tam J, Cinar R, Harvey-White J, Liu J, Mukhopadhyay B, Pacher P, Ming Mo F, Osei-Hyiaman D, Kunos G (2015) Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. Sci Rep. 5:14953.

  • Park O, Ki SH, Xu M, Wang H, Feng D, Tam J, Osei-Hyiaman D, Kunos G, Gao B (2015) Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell Biosci. 5:25.

 

  • Wasserman E, Tam J, Mechoulam R, Zimmer A, Maor G, Bab I (2015) CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Ann N Y Acad Sci. 1335:110-119.

2014

  • Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley B, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, Pacher P, Kunos G (2014) Overactive Cannabinoid 1 Receptor in Podocytes Drives Type-2 Diabetic Nephropathy. Proc.Natl.Acad.Sci U.S.A., 111:E5420-5428.

  • Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G (2014) Role of Adiponectin in the Metabolic Effects of Cannabinoid Receptor-1 Blockade in Mice with Diet-Induced Obesity. Am J Physiol Endocrinol Metab., 306:E457-468.

  • Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B, Harvey-White J, Kunos G (2014) Hepatic Cannabinoid-1 Receptors Mediate Diet-induced Insulin Resistance by Increasing de novo Synthesis of Long-chain Ceramides. Hepatology, 59:143-153.

2013

  • Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Ju C, Kunos G (2013) Activation of the Nlrp3 Inflammasome in Infiltrating Macrophages by Endocannabinoids Mediates Beta Cell Loss in Type 2 Diabetes. Nat. Med., 19:1132-1140.

 

  • Silverman MN, Mukhopadhyay P, Belyavskaya E, Tonelli LH, Revenis BD, Doran JH, Ballard BE, Tam J, Pacher P, Sternberg EM (2013) Glucocorticoid Receptor Dimerization is Required for Proper Recovery of LPS-induced Inflammation, Sickness Behavior and Metabolism in Mice. Mol. Psychiatry, 18:1006-1017.

2012

  • Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS, Innis RB, Cheng K, Rice KC, Deschamps JR, Chorvat RJ, McElroy JF, Kunos G (2012) Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance. Cell Metab., 16:167-179.

 

  • Srivastava S, Kashiwaya Y, King MT, Baxa U, Tam J, Niu G, Chen X, Clarke K, Veech RL (2012) Mitochondrial Biogenesis and Increased Uncoupling Protein 1 in Brown Adipose Tissue of Mice Fed a Ketone Ester Diet. FASEB J., 26:2351-2362.

 

  • Liu J, Zhou L, Xiong K, Godlewski G, Mukhoadhyay B, Tam J, Yin S, Gao P, Shan X, Pickel J, Bataller R, O’Hare J, Scherer T, Buettner C, Kunos G (2012) Hepatic Cannabinoid Receptor 1 Mediates Diet-induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice. Gastroenterology, 142:1218-1228.

    • Highlighted in Gastroenrerology, (2012) 142:1063-6

    • Selected for Faculty of 1,000 http://f1000.com/prime/716247804

2011

  • Kunos G, Tam J (2011) The Case for Peripheral CB1 Receptor Blockade in the Treatment of Visceral Obesity and its Cardiometabolic Complications. Br J Pharmacol., 163: 1423-1431.

 

  • Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, Harvey-White J, Mordi I, Cravatt BF, Lotersztajn S, Gao B, Yuan Q, Schuebel K, Goldman D, Kunos G (2011) Hyperactivation of Anandamide Synthesis and Regulation of Cell-cycle Progression via Cannabinoid Type 1 (CB1) Receptors in the Regenerating Liver. Proc.Natl.Acad.Sci U.S.A., 108:6323-6328.

  • Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G (2011) Endocannabinoids in Liver Disease. Hepatology, 53:346-355.

2010

  • Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, Osei-Hyiaman D, Liu J, Mukhopadhyay B, Harvey-White J, Tam J, Pacak K, Cravatt BF, Makriyannis A,  Kunos G (2010) Inhibitor of Fatty Acid Amide Hydrolase Normalizes Cardiovascular Function in Hypertension without Adverse Metabolic Effects. Chem.Biol., 17:1256–1266.

 

  • Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, Stuart JM, Bajayo A, Tam J, Kram V, O’Dell D, Walker MJ, Bradshaw HB, Bab I, Mechoulam R (2010) Oleoyl-serine, an Endogenous N-acyl Amide Modulates Bone Remodeling and Mass. Proc.Natl.Acad.Sci U.S.A., 107:17710-17715.

  • Tam J, Vemuri VK, Liu J, Bátkai C, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Makriyannis A, Kunos G (2010) Peripheral CB1 Cannabinoid Receptor Blockade Improves Cardiometabolic Risk in Mouse Models of Obesity. J Clin. Invest., 120:2953–2966.

  • Highlighted in J Clin. Invest., (2010) 120:2646-8.

2009

  • Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, Criswell B, Dixon A,  Lee C, Tam J, Kohler T, Segev E, Kockeritz L, Woodgett J, Müller R, Chai Y, Smith E, Bab I, Frenkel B (2009) Lef1 Haploinsufficient Mice Display a Low Turnover and Low Bone Mass Phenotype in a Gender- and Age-Specific Manner. PLoS One, 4:e5438.

2008

  • Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the Regulation of Bone Metabolism. J Neuroendocrinol, 20 Suppl 1:69-74.       

 

  • Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, Shteyer, A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E,  Bab I (2008) The Cannabinoid CB1 Receptor Regulates Bone Formation by Modulating Adrenergic Signaling. FASEB J, 22:285-294.

2006

  • Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus V, Shohami E, Bab I (2006) Depression Induces Bone Loss through Stimulation of the Sympathetic Nervous System. Proc.Natl.Acad.Sci U.S.A., 103:16876-16881.

 

  • Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Müller R, Zimmer A, Mackie K, Mechoulam R, Shohami E, Bab I (2006) Involvement of Neuronal Cannabinoid Receptor, CB1, in Regulation of Bone mass and Bone Remodeling. Mol.Pharmacol., 70:786-792.

 

  • Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral CB2 Cannabinoid Receptor Regulates Bone Mass. Proc.Natl.Acad.Sci U.S.A., 103:696-701.

Please reload